Mobile Diagnostics Without Compromise

The Challenges are Global

Clinicians need critical diagnostics earlier to empower the best, actionable care pathways.


The Value is Real

Empowered clinicians give millions the opportunity of timely treatment and improved patient outcomes.

Our Goal

Is to bring trusted diagnostics to the point of initial patient interaction, to expand access of quality healthcare to new settings, no matter where that patient interaction occurs




Nanomix Goals

NEWS


Internal Link

Nanōmix Appoints Finance Veteran Chris Hetterly as Chief Financial Officer

Nanōmix today announced the appointment of Christopher R. Hetterly as Chief Financial Officer (CFO)

Internal Link

Nanōmix Enters into Distribution Agreement for the eLab System with Gepa Srl in Italy

Nanōmix has announced that it has entered into a distribution agreement with Gepa Srl (“Gepa”), a distributor and supplier of diagnostic products in Italy.

Internal Link

Nanōmix Enters into an Exclusive Veterinary Distribution Agreement for the eLab System with Woodley Equipment Company, Ltd.

Nanōmix has entered into an exclusive distribution agreement with Woodley Equipment Company, Ltd. (“Woodley”), a global veterinary distributor.

Internal Link

Nanōmix Enters into Multi-Country Distribution Agreement for the eLab System with Mast Group Limited

Nanōmix has entered into a multi-region distribution agreement with Mast Group Limited (“Mast”), an independent world class manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing.

Internal Link

Nanōmix Enters into Distribution Agreement for the eLab System and Future New Products with Diaclinic SpA in Chile® Analyzer

Nanōmix Corporation announced a new distribution agreement with Diaclinic SpA, a medical distributor headquartered in Santiago, Chile. Diaclinic will market and distribute the Nanōmix eLab in the Republic of Chile.

Internal Link

Nanōmix Enters into Distribution Agreement for the eLab System and Future New Products with IPS Genomix s.a.l. in the Middle East

IPS will market and distribute the Nanōmix eLab® system, including the Nanōmix S1 Panel assay and future, new test products for the eLab system, in multiple countries throughout the Middle East.

*The Nanōmix eLab® and S1 Panel Cartridge has not yet been FDA reviewed or cleared for sale in the U.S. It is not commercially available in the U.S.
The Nanōmix eLab® and S1 Panel has received CE Mark and MHRA Registration.
The Nanōmix eLab® COVID-19 Rapid Antigen Test is not commercially available in the U.S.
The Nanōmix eLab® COVID-19 Rapid Antigen Test has received CE Mark.
Other assays in development